Latest Taysha Gene Therapies News & Updates

See the latest news and media coverage for Taysha. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Taysha Gene Therapies (Taysha)

Gene therapy company for CNS monogenic diseases

tayshagtx.com
Headquarters
Dallas, United States
Founded year
2020
Company type
Public company
Number of employees
125–200
Industry
Pharmaceuticals

Last updated

Latest news about Taysha Gene Therapies (Taysha)

In short: Taysha completed dosing in its TSHA-102 pivotal trial for Rett syndrome and secured $230 million to support its path toward a 2027 BLA.

Company announcements

Taysha

Taysha announces proposed $200M public offering of common stock

The offering includes common stock and pre-funded warrants, with underwriters' option for additional 15%.

Unlock all announcements with a

Media coverage

Markets Insider

Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6‑month interim analysis...

Unlock all articles with a

Never miss news about Taysha

Track Taysha and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Taysha competitors & trending companies

Browse news for competitors to Taysha and other trending companies.